User:Brittany Stankavich/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 17: | Line 17: | ||
== Signal Transduction == | == Signal Transduction == | ||
- | [[Image:Gpr40 insulin pathway.png| | + | [[Image:Gpr40 insulin pathway.png|400 px|center|hGPR40]] |
FFAs bind to GPR40 which then couples with the G-protein Gq leading to increased phospholipase C (PLC) activity. PLC catalyzes the hydrolysis of the phospholipid phosphatidylinositol-4,5-biphosphate (PIP2) resulting in the formation of diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG can activate protein kinase C (PKC) to enhance insulin secretion. IP3 on the other hand is soluble and diffuses to the endoplasmic reticulum where it is able to bind to a receptor on a ligand-gated Ca2+ channel. This binding triggers the opening of the channel causing stored Ca2+ to be released into the cytoplasm. Upon this large increase in intracellular free Ca2+, there is also an increase in glucose-dependent insulin secretion suggesting that insulin release can be contributed in part to the changes in Ca2+ concentration resulting from activated GPR40. | FFAs bind to GPR40 which then couples with the G-protein Gq leading to increased phospholipase C (PLC) activity. PLC catalyzes the hydrolysis of the phospholipid phosphatidylinositol-4,5-biphosphate (PIP2) resulting in the formation of diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG can activate protein kinase C (PKC) to enhance insulin secretion. IP3 on the other hand is soluble and diffuses to the endoplasmic reticulum where it is able to bind to a receptor on a ligand-gated Ca2+ channel. This binding triggers the opening of the channel causing stored Ca2+ to be released into the cytoplasm. Upon this large increase in intracellular free Ca2+, there is also an increase in glucose-dependent insulin secretion suggesting that insulin release can be contributed in part to the changes in Ca2+ concentration resulting from activated GPR40. |
Revision as of 18:50, 1 April 2016
- User:Brittany Stankavich/Sandbox 1
hGPR40 Homo sapiens
|
References
- ↑ Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG, Han GW, Kuhn P, Rosen H, Stevens RC. Crystal structure of a lipid G protein-coupled receptor. Science. 2012 Feb 17;335(6070):851-5. PMID:22344443 doi:10.1126/science.1215904
- ↑ Li X, Zhong K, Guo Z, Zhong D, Chen X. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metab Dispos. 2015 Nov;43(11):1751-9. doi: 10.1124/dmd.115.064121. Epub 2015, Aug 14. PMID:26276582 doi:http://dx.doi.org/10.1124/dmd.115.064121
- ↑ 3.0 3.1 Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata T, Watanabe N, Hirouchi M, Yoneyama T, Ito S, Toda N. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan 13;6(3):266-70. doi: 10.1021/ml500391n. eCollection, 2015 Mar 12. PMID:25815144 doi:http://dx.doi.org/10.1021/ml500391n